



# Biotechnology and Pharmaceuticals

in the Capital Region Berlin-Brandenburg



Takeda's Oranienburg location – center of excellence for fixed forms in the worldwide production network



The CoLaborator from Bayer provides the perfect environment for young companies in the life sciences.

### Biotech

- Analyticon Discovery
- BIOTECON Diagnostics
- Co.don
- Epigenomics
- Glycotope
- Ifp Institut für Produktqualität
- In.vent DIAGNOSTICA
- InVivo Biotech Services
- JPT Peptide Technologies
- KNAUER
- Wissenschaftliche Geräte
- LGC
- metanomics
- MOLOGEN
- NOXXON Pharma
- Omeicos Therapeutics
- Organobalance
- ProBioGen
- Seramun Diagnostica
- SGS INSTITUT
- FRESENIUS Berlin
- SIFIN
- Silence Therapeutics
- Thermo Fisher Scientific – B·R·A·H·M·S
- TIB MOLBIOL

For a complete overview of all the companies, see our Life Sciences Report.

## Leading European location for biotechnology

Biotechnology is an engine of innovation in the Berlin-Brandenburg region. The sector is recording steady growth and a high rate of company startups. This positive trend is based on the region's excellent research landscape and technology parks specialized in biotechnology. They provide optimal conditions for startups and large, research-intensive companies alike. Of the more than 240 biotechnology companies with approx. 5,000 employees here, 80% focus on biomedicine. They develop innovative therapeutic and diagnostic procedures for the treatment of cancer, cardiovascular diseases and diabetes, and benefit from the region's excellent science and top infrastructure for clinical studies. Berlin-Brandenburg possesses expertise in genome and proteome research, diagnostics, regenerative medicine, RNA technologies and glyco-engineering technology.



»The Berlin-Brandenburg metropolitan area is a unique place inside the German healthcare sector. Nowhere else in Germany will you find a comparable concentration of world class science, hospitals and industry. This cross-functional cluster turns the German capital

region into a true magnet for healthcare investments in Europe.«

**Stefan Oelrich**  
Member of the Board of Management  
President Pharmaceuticals  
Bayer AG



»The technology for our innovative vaccines originated at the Max Planck Institute of Colloids and Interfaces which is located in the greater Berlin area. So it was natural to locate Vaxxilon in the region. We received excellent support from the Adlershof Technology Park to

establish our offices and laboratories.«

**Dr. Clane Pereira**  
General Manager  
Vaxxilon Deutschland GmbH

## Pharmaceutical location with a rich history and modern dynamics

The sustained success of pharmaceutical industry in Berlin and Brandenburg is based on innovative products and a venerable tradition reaching back to the 19th century. The sector benefits from an excellent scientific environment and clinical research landscape, and its proximity to the health care system decision makers. This applies to global players such as Bayer, Pfizer, Sanofi, Takeda and Berlin-Chemie (Menarini) and to more than 20 additional medium-sized pharmaceuticals companies with a total of 10,000 employees. Many international corporations such as Daiichi Sankyo and Astra Zeneca also have representative offices in Berlin.

Bayer can look back at a long history in Berlin. Today, the company is one of the world's leading speciality pharmaceuticals companies. More than 1,000 Sanofi employees manage the company's marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Takeda is currently investing €100 million to expand its production facilities in Oranienburg.



Production of biomarkers at B.R.A.H.M.S GmbH in Hennigsdorf

- Leading German biotechnology location with over 240 companies in the sector
- Pharmaceutical location with a rich history
- Outstanding conditions for clinical research
- Excellent access to skilled specialists due to the many degree, training and continuing education programs
- Outstanding science landscape featuring Charité – Universitätsmedizin Berlin and many other university and non-university research institutions (Max Planck, Fraunhofer and Leibniz Institutes and the Helmholtz Centers)
- Political center and seat of the vfa, BPI and BIO Deutschland sector associations, as well as health insurance companies and patient organisations
- Tight network among science and business through interdisciplinary partnerships in the areas of biotechnology, diagnostics, pharmaceuticals, medical technology, photonics and ICT

Pharmaceutical giant Pfizer is also expanding its activities in the capital region, establishing other business units to supplement its German headquarters here. For example, the company manages its oncology business unit for Europe from Berlin. In 2014 Riemser Pharma reinforced its sales activities with an operations-related unit in Berlin. In 2015 Boehringer Ingelheim opened a representative office in the capital. Berlin-Chemie is investing €80 million to expand its production facilities in the south of Berlin. Dr. Kade, which has been growing in the capital region for over 25 years, has taken over Takeda's OTC business. And the fact that Klosterfrau Berlin invested in a new production hall also shows that Berlin has developed into an important production location in recent years.

## Clinical research

The close connection between research, development and the clinics here is most obviously demonstrated by the region's successful, well-established translational research and the wide range of opportunities available for implementing clinical studies. With its large, extremely diverse patient collective, Berlin-



»We founded OMEICOS Therapeutics on the base of research results, generated at the Max-Delbrück-Center for Molecular Medicine. Our continuous close collaboration with MDC and other partners in Berlin is of great value for OMEICOS' success. As pioneers in the field of

synthetic omega-3 epoxyeicosanoid analogs, we are developing small molecules for cardiovascular and ophthalmic indications.«

**Dr. Karen Uhlmann**  
 Director Legal Corporate & Operations  
 OMEICOS Therapeutics GmbH



»The Berlin-Brandenburg region is a leading location for healthcare in Germany. The proximity to science and research, and also to health policy actors, make it the ideal location for our sales center and one of our production facilities. In producing and distributing mostly speciality drugs, we employ over 1,000 workers and trainees in Berlin and Brandenburg.«

**Günter Kloucek**  
 CEO  
 Takeda Pharma Vertrieb GmbH & Co. KG

Brandenburg facilitates all kinds of clinical research projects. Charité – Universitätsmedizin Berlin and CROs such as Parexel – active with over 1,000 employees in Berlin – and other smaller providers that supervise studies of all types all play outstanding roles in this area.

## Optimal conditions for startups

The nine biotechnology parks in the region provide optimal conditions for young, growing companies. Over 50% of the biotechnology companies use the programs of the state-owned or privately operated parks, which offer a variety of contextual focal areas. In addition to the availability of laboratory space and an extensive technical infrastructure, they benefit from the close contact and intense exchange with the research institutions and multi-faceted service providers that are also located in the parks.

When it comes to early stage financing, the states' own business development banks have investment companies whose technology funds play an important role. Projects such as Bayer's CoLaborator are evidence of the major pharmaceuticals corporations' involvement.

### Pharma

Aenova/  
 Haupt Pharma Berlin  
 Aristo Pharma  
 Bausch + Lomb  
 Bayer  
 Berlin-Chemie (Menarini Group)  
 DR. KADE  
 Pharmazeutische Fabrik  
 Klosterfrau Berlin  
 Merz Pharmaceuticals  
 Next Pharma  
 Pfizer  
 Riemser Pharma  
 Sanofi  
 Shire  
 Takeda Pharma

### Networks

BioResponse Network  
 DiagnostikNet-BB  
 glyconet Berlin  
 Brandenburg  
 NetPhaSol

### Biotech-Parks

berlinbiotechpark  
 Biotech Campus Potsdam  
 Biotechnologiepark  
 Luckenwalde  
 Campus Berlin-Buch  
 co:bios Technologiezentrum  
 Hennigsdorf  
 GO:IN Golm Innovationszentrum, Potsdam  
 Science and Technology  
 Park Adlershof  
 Techno Terrain Teltow  
 Wuhlheide Innovation Park



**HealthCapital**  
BERLIN BRANDENBURG

## Our aim: your success!

Berlin and Brandenburg support the biotechnology and pharma focal area with an economic policy developed across state borders in the Healthcare industries cluster. The cluster is managed under the aegis of Berlin Partner for Business and Technology and the Brandenburg Economic Development Corporation.

Our aim is to provide comprehensive support to companies and scientific institutions interested in inward investment or further development in the capital region.

We are ready to assist you with:

- **Company start-up**
- **Location search**
- **Funding and financing**
- **Technology transfer and R&D partnerships**
- **Cooperating in networks**
- **Employee recruiting, programs designed to retain skilled specialists and qualification**
- **International market development**

Reach out and contact us!

[www.healthcapital.de](http://www.healthcapital.de)

**PHOTOS:** Cover: YAZ-Flex production in Berlin, Bayer. Inside: Takeda/Sebastian Bolesch, Bayer, B•R•A•H•M•S  
**DESIGN:** Büro Watkinson, Berlin. **PRINT:** LASERLINE, Berlin

© November 2018



**Berlin Partner für Wirtschaft und Technologie GmbH**

Fasanenstr. 85  
10623 Berlin  
[www.berlin-partner.de](http://www.berlin-partner.de)  
Twitter: @BerlinPartner

**Contact:**  
Carolin Clement  
T +49 30 46302 430  
[carolin.clement@berlin-partner.de](mailto:carolin.clement@berlin-partner.de)

**Brandenburg Invest | WFBB**

**Wirtschaftsförderung Land Brandenburg GmbH**  
Babelsberger Straße 21  
14473 Potsdam  
[www.wfbb.de](http://www.wfbb.de)

**Contact:**  
Stefan Bauer  
T +49 331 20029 253  
[stefan.bauer@wfbb.de](mailto:stefan.bauer@wfbb.de)



Publisher: Berlin Partner for Business and Technology in cooperation with the Brandenburg Economic Development Corporation. Funded by the State of Berlin and the European Regional Development Fund through the Investitionsbank Berlin.